The document summarizes key details of new oral anticoagulant drugs (NOADs) that are alternatives to warfarin for preventing strokes. It lists 5 NOADs - dabigatran, rivaroxaban, apixaban, edoxaban - along with their brand names, FDA approval dates, dosing information, costs, and reversal agents. It also provides a brief overview of each drug's pharmacokinetic properties including time to peak levels, half-life, drug interactions, and renal clearance compared to warfarin. The document concludes by summarizing findings from major clinical trials on each NOAD's efficacy and safety compared to warfarin in reducing risks of stroke, intracranial